Table 4.
Summary of ROS associated miRNAs in cancer.
Name | Associated cancer type | Target | Influence to ROS | Model of evidence | Reference |
---|---|---|---|---|---|
miR-124 | Non-small cell lung cancer | TXNRD1 | Up | Cell culture | 120 |
miR-125a | Osteosarcoma | Estrogen-related receptor alpha | Up | Cell culture | 229 |
miR-128a | Medulloblastoma | BMI-1 | Up | Cell culture | 230 |
miR-139-5p | Breast cancer | Unknown | Up | Cell culture, animal models | 231 |
miR-143 | Colorectal cancer | SOD1 | Up | Cell culture | 121 |
miR-146a | Lung cancer, ovarian Cancer | Catalase, SOD2 | Up | Cell culture, animal models | 117,118 |
miR-146b-5p | Leukemic | Unknown | Up | Cell culture | 232 |
miR-15 | Colorectal cancer, cancer stem cells | C-MYC | Up | Cell culture, animal models | 233 |
miR-155 | Glioma, pancreatic cancer | MAPK13, MAPK14, and Foxo3a | Up | Cell culture, animal models | 234,235 |
miR-15a-3p | Lung cancer | P53 | Up | Cell culture | 236 |
miR-16 | Colorectal cancer, cancer stem cells | C-MYC | Up | Cell culture, animal models | 233 |
miR-186 | Colorectal cancer | CKII | Up | Cell culture | 237 |
miR-193a-3p | Glioma | γH2AX | Up | Cell culture | 238 |
miR-210 | Cancer stem cells, glioma | P53 | Up | Cell culture, animal models | 239 |
miR-212 | Colorectal cancer | MnSOD | Up | Clinical samples | 240 |
miR-216b | Colorectal cancer | CKII | Up | Cell culture | 237 |
miR-22 | Hepatocellular carcinoma | SIRT-1 | Up | Cell culture | 241 |
miR-223 | Breast cancer | HAX-1 | Up | Cell culture | 242 |
miR-23b-3p | Acute myeloid leukemia | PrxIII | Up | Cell culture | 243 |
miR-25-5p | Colorectal cancer | SOX10 | Up | Cell culture | 244 |
miR-26a-5p | Acute myeloid leukemia | PrxIII | Up | Cell culture | 243 |
miR-26b | Small cell lung cancer | Myeloid cell leukemia 1 protein | Up | Cell culture, animal models | 245 |
miR-30 | Gastric cancer | P53 | Up | Cell culture | 246 |
miR-337-3p | Colorectal cancer | CKII | Up | Cell culture | 237 |
miR-34c | Nonsmall cell lung cancer | HMGB1 | Up | Cell culture | 247 |
miR-371-3p | Lung cancer | PRDX6 | Up | Cell culture, animal models | 248 |
miR-422a | Gastric cancer | PDK2 | Up | Cell culture, animal models | 249 |
miR-4485 | Breast cancer | Mitochondrial protein | Up | Cell culture, animal models | 133 |
miR-4673 | Lung cancer | 8-Oxoguanine-DNA Glycosylase-1 | Up | Cell culture | 250 |
miR-504 | Lung cancer | P53 | Up | Cell culture | 251 |
miR-506 | Lung cancer | P53, NF-κB | Up | Cell culture, animal models | 252 |
miR-509 | Breast cancer | P53 | Up | Cell culture | 253 |
miR-526b | Breast cancer | Thioredoxin Reductase 1 | Up | Cell culture | 119 |
miR-551b | Lung cancer | MUC1 | Up | Cell culture | 254 |
miR-655 | Breast cancer | Thioredoxin Reductase 1 | Up | Cell culture | 119 |
miR-661 | Colorectal cancer | Hexose-6-phosphate dehydrogenase, pyruvate kinase M2 | Up | Cell culture | 255 |
miR-760 | Colorectal cancer | CKII | Up | Cell culture | 237 |
miR-92 | Hepatocellular carcinoma | Unknown | Up | Clinical samples | 256 |
miR-128 | Glioma, hepatocellular carcinoma | PKM2 | Up/Down | Cell culture | 257 |
miR-145 | Colorectal cancer, hepatocellular carcinoma | SOD1, PKM2 | Up/Down | Cell culture | 121,258 |
miR-211 | Myeloma, oral carcinoma | PRKAA1, TCF12 | Up/Down | Cell culture, animal models | 259,260 |
miR-222 | Hepatocellular carcinoma, breast cancer | NF-κB, TGF-β | Up/Down | Cell culture, animal models | 261,262 |
miR-23a/b | Myeloma, renal cancer | C-MYC, POX | Up/Down | Cell culture, animal models | 263,264 |
miR-29 | Ovarian cancer, lung cancer, and lymphoma | C-MYC, SIRT1 | Up/Down | Cell culture, animal models | 265,266 |
miR-34a | Gastric cancer, glioma | NOX2 | Up/Down | Cell culture | 267 |
Let-7 | Hepatocellular carcinoma, prostate cancer, and pancreatic cancer | Heme oxygenase-1, P53 | Up/Down | Cell culture, animal models | 123,268 |
miR-33a | Glioma, hepatocellular carcinoma | SIRT6 | Up/Down | Cell culture, animal models | 269 |
miR-221 | Hepatocellular carcinoma, breast cancer | NF-κB, TGF-β, and DICER | Up/Down/Induced by ROS | Cell culture, animal models | 261,262,270 |
miR-21 | Lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer, and prostate cancer | SOD, MAPK, SOD2, Glucose, NFκB, STAT3, POX, and PDCD4 | Up/Down/Induced by ROS | Cell culture, animal models | 108,112,114,271 |
miR-17-92 | Gastric cancer, lung cancer | C-MYC, P53, and NFκB | Up/Down/Inhibited by ROS | Cell culture | 137,272,273 |
miR-181 | Hepatocellular carcinoma, uterine leiomyoma | Unknown | Up/Induced by ROS | Cell culture | 132,274 |
miR-200 | Breast cancer, cancer stem cells, hepatocellular carcinoma, and lung cancer | P53, PRDX2, GAPB/NRF2, SESN1 | Up/Induced by ROS | Cell culture, animal models | 222,275–277 |
miR-34 | Cancer stem cells, bladder cancer, lung cancer | C-MYC, P53 | Up/Induced by ROS | Cell culture | 278,279 |
miR-182 | Uterine leiomyoma, lung cancer | PDK4 | Up/Induced by ROS | Cell culture, animal models | 132,133 |
miR-199 | Gastric cancer, ovarian cancer | DNMT1 | Up/Inhibited by ROS | Cell culture | 134 |
miR-20a | Breast cancer, pancreatic cancer | BECN1, ATG16L1, and SQSTM1 | Up/Inhibited by ROS | Cell culture, animal models | 136,280 |
miR-125b | Hepatocellular carcinoma, ovarian cancer, and breast cancer | Hexokinase 2, DNMT1, and HAX-1 | Up/Inhibited by ROS | Cell culture, animal models | 228,281 |
miR-1246 | Breast cancer | NF-κB, TGF-β | Down | Cell culture | 124 |
miR-137 | Ovarian cancer | C-MYC | Down | Cell culture, animal models | 125 |
miR-193b | Liposarcoma | Antioxidant methionine sulfoxide reductase A | Down | Cell culture, animal models | 127 |
miR-199a-3p | Testicular cancer | Transcription factor specificity protein 1 | Down | Cell culture | 126 |
miR-26a | Hepatocellular carcinoma | Triglyceride, totalcholesterol, malondialdehyde | Down | Cell culture | 128 |
miR-30c-2-3p | Breast cancer | NF-κB, TGF-β | Down | Cell culture | 282 |
miR-346 | Ovarian cancer | GSK3B | Down | Cell culture | 283 |
miR-373 | Breast cancer | NF-κB, TGF-β | Down | Cell culture, animal models | 123 |
miR-520 | Breast cancer | NF-κB, TGF-β | Down | Cell culture, animal models | 123 |
miR-7 | Nonsmall cell lung cancer | MAFG | Down | Cell culture | 284 |
miR-885-5p | Hepatocellular carcinoma | TIGAR | Down | Cell culture | 285 |
miR-99a | Lung cancer | NOX4 | Down | Cell culture, animal models | 122 |
miR-133a | Rhabdomyosarcoma | 9 | Induced by ROS | Cell culture, animal models | 129 |
miR-150-3p | Hepatocellular carcinoma | – | Induced by ROS | Cell culture | 130 |
miR-1915-3p | Hepatocellular Carcinoma | – | Induced by ROS | Cell culture | 130 |
miR-206 | Rhabdomyosarcoma | – | Induced by ROS | Cell culture, animal models | 131 |
miR-34a-3p | Hepatocellular carcinoma | – | Induced by ROS | Cell culture, animal models | 129 |
miR-34a-5p | Hepatocellular carcinoma | – | Induced by ROS | Cell culture | 130 |
miR-638 | Hepatocellular carcinoma | – | Induced by ROS | Cell culture | 130 |
miR-125 | Gastric cancer | – | Inhibited by ROS | Cell culture | 134 |
miR-145-5p | Gastric cancer | – | Inhibited by ROS | Cell culture, animal models | 135 |
miR-17-5p | Pancreatic cancer | – | Inhibited by ROS | Cell culture, animal models | 136 |
miR-27a | Pancreatic cancer, colorectal cancer | – | Inhibited by ROS | Cell culture, animal models | 286 |
miR-328 | Gastric cancer | – | Inhibited by ROS | Cell culture, animal models | 287 |
miR-329 | Breast cancer | – | Inhibited by ROS | Cell culture, animal models | 288 |
miR-362-3p | Breast cancer | – | Inhibited by ROS | Cell culture, animal models | 288 |